ST. LOUIS, Dec. 6, 2018 /PRNewswire/ -- Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). This novel drug candidate represents a new strategy for treating bacterial infections by preventing the bacteria that cause UTIs from sticking to the walls of the bladder, thus allowing the body to naturally eliminate the infection. Since this mannose-containing compound does not kill bacteria, it potentially could treat and prevent UTIs without inducing antibiotic resistance. "We are thrilled to have hit this candidate selection milestone with GSK," Dr. Scott Hultgren, co-founder and board member of Fimbrion, said. About DPAC - Discovery Partnerships with Academia (DPAc) is an innovative approach to drug discovery. As a unit within GSK's research and development organization, DPAc is dedicated to creating highly collaborative relationships with leading academic researchers to develop new medicines that truly benefit patients.
1 other references
Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract InfectionsPublished on 06/12/2018 02:06 by: www.prnewswire.co.uk
Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract InfectionsPublished on 06/12/2018 02:07 by: www.prnewswire.com
Latest Stories From Referenced Companies
Pediatric Epilepsy Therapeutics Markets, 2019-2023 - The Global Industry is Dominated by Eisai, GlaxoSmithKline, GW Pharmaceuticals, Pfizer, and UCB
Dec 11, 2018
Dec 11, 2018